RxDoctor Payments Data

Bryce Robison, MD

Family Medicine · Sioux City, IANPI 1235190968

Payments from drug & device makers

$758in general payments, 2019–2025

Across 42 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$393
  • Davol Inc.$164
  • AbbVie$114
  • E.r. Squibb & Sons, L.L.C.$44
  • Amgen$15
  • Eisai Inc.$15
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$758100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer28$393
Davol Inc.1$164
AbbVie(2 entities)7$114
E.r. Squibb & Sons, L.L.C.3$44
Amgen1$15
Eisai Inc.1$15
Hologic Sales And Service, LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$758 in reported general payments places this provider in the 75th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$413,169
Medicare patients
701
Services billed
21,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban212$121,151
JardianceEmpagliflozin68$76,492
OzempicSemaglutide44$52,255
FarxigaDapagliflozin Propanediol76$44,031
XareltoRivaroxaban34$24,919
JanuviaSitagliptin Phosphate28$17,971
Breo ElliptaFluticasone/Vilanterol27$9,763
LinzessLinaclotide12$6,882
MyrbetriqMirabegron27$6,186
Atorvastatin Calcium684$5,101
Levothyroxine Sodium798$5,015
Omeprazole496$4,740
VytorinEzetimibe/Simvastatin12$4,634
Metoprolol Succinate394$3,737
Gabapentin205$3,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$393$121,151212 claims
AbbVieLinzess, Synthroid$114$9,43136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Sioux City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →